Aquestive Therapeutics Announces Resubmission Of NDA To FDA For Anaphylm Sublingual Film For Type I Allergic Reactions

8-K filing — Aquestive Therapeutics, Inc. (AQST)

Filed: 2026-09-29 AccNo: 0001398733-26-000052 Size: 1 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

Aquestive Therapeutics has resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film for severe allergic reactions.

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target